

Selective peroxisome proliferator-activated receptor- modulator K-877 efficiently activates the peroxisome proliferator-activated receptor- pathway and improves lipid metabolism in mice

著者別名	松坂 賢, 関谷 元博, 岩? 仁, 矢藤 繁, 矢作 直也, 鈴木 浩明, 中川 嘉, 島野 仁
journal or publication title	Journal of Diabetes Investigation
volume	8
number	4
page range	446-452
year	2017-07
権利	(C) 2017 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
URL	http://hdl.handle.net/2241/00146890

doi: 10.1111/jdi.12621

Selective peroxisome proliferator-activated receptor- α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor- α pathway and improves lipid metabolism in mice

Kenta Takei^{1†}, Song-lee Han^{1†}, Yuki Murayama^{1†}, Aoi Satoh¹, Fusaka Oikawa¹, Hiroshi Ohno¹, Yoshinori Osaki¹, Takashi Matsuzaka¹, Motohiro Sekiya¹, Hitoshi Iwasaki¹, Shigeru Yatcho¹, Naoya Yahagi¹, Hiroaki Suzuki¹, Nobuhiro Yamada¹, Yoshimi Nakagawa^{1,2}, Hitoshi Shimano^{1,2,3*}

¹Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, ²International Institute for Integrative Sleep Medicine (WPI-IIS), and ³Life Science Center, Tsukuba Advanced Research Alliance (TARA), University of Tsukuba, Tsukuba, Ibaraki, Japan

Keywords

Lipid metabolism, Peroxisome proliferator-activated receptor- α , Selective peroxisome proliferator-activated receptor- α modulator

*Correspondence

Hitoshi Shimano
 Tel.: +81-29-853-3053
 Fax: +81-29-853-3174
 E-mail address: hshimano@md.tsukuba.ac.jp

J Diabetes Investig 2017; 8: 446–452

doi:10.1111/jdi.12621

ABSTRACT

Aims/Introduction: Peroxisome proliferator-activated receptor- α (PPAR α) is a therapeutic target for hyperlipidemia. K-877 is a new selective PPAR α modulator (SPPARM α) that activates PPAR α transcriptional activity. The aim of the present study was to assess the effects of K-877 on lipid metabolism *in vitro* and *in vivo* compared with those of classical PPAR α agonists.

Materials and Methods: To compare the effects of K-877 on PPAR α transcriptional activity with those of the classical PPAR α agonists Wy14643 (Wy) and fenofibrate (Feno), the cell-based PPAR α transactivation luciferase assay was carried out. WT and *Ppara*^{-/-} mice were fed with a moderate-fat (MF) diet for 6 days, and methionine–choline-deficient (MCD) diet for 4 weeks containing Feno or K-877.

Results: In luciferase assays, K-877 activated PPAR α transcriptional activity more efficiently than the classical PPAR α agonists Feno and Wy. After being fed MF diet containing 0.001% K-877 or 0.2% Feno for 6 days, mice in the K-877 group showed significant increases in the expression of *Ppara* and its target genes, leading to marked reductions in plasma triglyceride levels compared with those observed in Feno-treated animals. These K-877 effects were blunted in *Ppara*^{-/-} mice, confirming that K-877 activates PPAR α . In further experiments, K-877 (0.00025%) and Feno (0.1%) equally improved the pathology of MCD diet-induced non-alcoholic fatty liver disease, with increased expression of hepatic fatty acid oxidation genes.

Conclusions: The present data show that K-877 is an attractive PPAR α -modulating drug and can efficiently reduce plasma triglyceride levels, thereby alleviating the dysregulation of lipid metabolism.

INTRODUCTION

Impaired nutrient homeostasis is a common characteristic of metabolic disorders, such as obesity, diabetes, cardiovascular

diseases and fatty liver disease. Nutrient homeostasis is tightly regulated through the balance between energy-producing pathways, such as ketogenesis, gluconeogenesis and lipid synthesis, and energy utilization pathways, such as lipid oxidation. Because of the emerging epidemic of obesity and diabetes, the factors determining progression of non-alcoholic fatty liver

[†]These authors contributed equally to this work.
 Received 18 September 2016; revised 21 December 2016; accepted 10 January 2017

disease (NAFLD) present a major clinical challenge. In particular, fatty liver can progress to non-alcoholic steatohepatitis (NASH) after overwhelming of the adaptive mechanisms that mediate lipid partitioning and metabolism, and protect hepatocytes from lipotoxicity of excess fatty acids (FAs) and other lipids, resulting in inflammation and fibrosis.

Peroxisome proliferative-activated receptors (PPARs) are members of the nuclear receptor superfamily, and include PPAR α , PPAR β/δ and PPAR γ . On ligand binding, PPARs form heterodimers with the retinoid X receptor, and interact with PPAR response elements to regulate target gene expression. PPAR α is most prominently expressed in the liver, and is activated by hypolipidemic fibrate-class drugs (fibrates). PPAR α controls lipid flux in the liver by modulating FA transport and β -oxidation, and improves plasma lipid profiles by decreasing triglyceride (TG) levels and increasing high-density lipoprotein cholesterol levels. In addition, PPAR α activation inhibits inflammatory genes that are induced by nuclear factor- κ B, and decreases the expression of acute-phase response genes. Accordingly, PPAR α deficiency increases susceptibility to NAFLD, NASH, hepatic inflammation and acute phase responses¹. Fibrates, such as gemfibrozil, bezafibrate, and fenofibrate (Feno), decrease plasma TG levels, and increase high-density lipoprotein cholesterol levels in patients with hyperlipidemia and type 2 diabetes, and can prevent coronary heart disease and stroke^{2–6}. However, these drugs are weak agonists of PPAR α , have poor substrate selectivity and require high clinical doses. Therefore, a potent and selective PPAR α agonist is required for patients with metabolic syndrome. K-877 is a novel selective PPAR α modulator (SPPARM α) that enhances PPAR α activity⁷; it also elicits higher PPAR α activation than other fibrates, with lower EC₅₀ values and higher PPAR subtype selectivity⁸.

In the present study, we compared the effects of K-877 on lipid metabolism and hepatic gene expression related to NASH/NAFLD with the classical PPAR α agonists, Feno and Wy14643 (Wy), *in vitro* and *in vivo*.

MATERIALS AND METHODS

Reagents

K-877 was kindly provided by Kowa Co. Ltd. Feno and Wy were purchased from Sigma-Aldrich (St. Louis, Missouri, USA).

Animals

Eight-week-old male C57BL/6J (wild-type; WT) mice were obtained from CLEA Japan (Tokyo, Japan). B6;129S4-*Ppara*^{tm1Gonz/J} (*Ppara*^{-/-}) mice were purchased from the Jackson Laboratory (Bar Harbor, Maine, USA). Methionine–choline-deficient (MCD)-diet analyses were carried out on 8-week-old male mice that were fed for 4 weeks and killed without fasting. All animal husbandry procedures and experiments were compliant with the University of Tsukuba's Regulations for Animal Experiments, and were approved by the Animal Experiment Committee at the University of Tsukuba.

Histological analysis

Harvested livers were fixed, embedded in paraffin, sectioned and stained with hematoxylin–eosin.

Plasmids

The expression vector for the Gal4-PPAR α (pM Gal4-PPAR α) fusion protein was generated by inserting a human PPAR α fragment (166–468 aa) downstream of Gal4 in the pM vector (Clontech, Palo Alto, California, USA). The GAL4 UAS-LUC vector contains eight copies of the UAS Gal4-binding site⁹.

Cell culture

Mouse AML12.2 hepatoma cells were maintained in Dulbecco's modified Eagle's medium/Ham's F12 media supplemented with ITS Liquid Media Supplement (Sigma-Aldrich), 100 U/mL penicillin, 100 μ g/mL streptomycin and 10% fetal bovine serum. Cells were incubated with Feno (50 μ mol/L) or K-877 (5 and 50 μ mol/L) for 48 h.

Transfections and Luc assays

HepG2 cells were grown at 37°C in an atmosphere of 5% CO₂ in Dulbecco's modified Eagle's medium containing 25 mmol/L glucose, 100 U/mL penicillin, 100 μ g/mL streptomycin and 10% fetal bovine serum. Transfection studies were carried out in cells on 24-well plates. Cells were transfected with pM Gal4-PPAR α DBD and GAL4 UAS luciferase vectors⁹, and a pRL-SV40 plasmid as a reference (Promega, Madison, Wisconsin, USA) using X-tremeGENE 9 (Roche, Basel, Switzerland). After 24 h of transfection, Wy (50 μ mol/L), Feno (30 μ mol/L) or K-877 (50 nmol/L) were added to the medium. After additional 24-h incubation, firefly luciferase activity was measured and normalized to that of *Renilla*.

Metabolic measurements

Plasma levels of TG, non-esterified FA (NEFA), total cholesterol (TC), aspartate aminotransferase, alanine aminotransferase, and liver TG and TC levels were measured as described previously¹⁰.

Analysis of gene expression

Total ribonucleic acid from cells and tissues was prepared using a Trizol reagent (Invitrogen, Carlsbad, California, USA). Before real-time polymerase chain reaction analyses, total ribonucleic acid was reversed transcribed into complementary deoxyribonucleic acid using a reverse transcriptase according to the manufacturer's instructions (Invitrogen). Real-time polymerase chain reaction was carried out using an ABI Prism 7300 system (ABI, Carlsbad, California, USA) with TaqMan probes (Invitrogen) and a SYBR Green Master Mix (Roche)¹¹. Primer sequences are available on request.

Statistical analysis

Comparisons of treatment groups were made using Tukey–Kramer post-hoc tests, and differences were considered significant




Figure 1 | K-877 activates the Peroxisome proliferator-activated receptor- α (PPAR α) transcriptional activity. (a,b) HepG2 cells were co-transfected with GAL4 UAS-LUC and pM GAL4-hPPAR α ligand-binding domain vectors, and with a pRL-SV40 plasmid as a reference in 24-well plates for 24 h. Cells were then treated with Wy, Feno or K-877 for 48 h, and were harvested at 48 h after transfection. Luciferase activity was measured and normalized to that of *Renilla* luciferase activity. (a) Dose–response curves of PPAR α transactivation. (b) Cells were then treated with Wy14643 (Wy; 50 μ mol/L), fenofibrate (Feno; 30 μ mol/L) or K-877 (50 nmol/L); $n = 8$ per group. (c) AML12.2 cells were treated with Feno (50 μ mol/L) or K-877 (5 and 50 μ mol/L) for 48 h. *Fgf21* expression was determined by quantitative polymerase chain reaction; $n = 9$ per group, * $P < 0.05$ and ** $P < 0.01$.

when $P < 0.05$. All data are expressed as mean \pm standard error of the mean.

RESULTS

K-877 effectively activates PPAR α transcriptional activity

To compare the effects of K-877 on PPAR α transcriptional activity with those of the classical PPAR α agonists Wy and Feno, cell-based transactivation assays were carried out using a Gal4-luciferase assay system. After co-transfecting human HepG2 hepatoma cells with pM-GAL4 PPAR α ligand-binding domain and GAL4 UAS reporter vectors, cells were treated with K-877 for 24 h. Although K-877, Wy and Feno induced PPAR α luciferase activation in a dose-dependent manner, the dose–response curve of K-877 was shifted to the left side compared with those of Wy14643 and Feno (Figure 1a). K-877 is a highly potent agonist of PPAR α transcriptional activity, with half-maximal effective concentrations (EC₅₀) of 0.49 nmol/L. The PPAR α agonists, Wy (50 μ mol/L), Feno (30 μ mol/L) or K-877 (50 nmol/L) were treated for 24 h. PPAR α luciferase activation by K-877 was comparable with that by Wy or Feno (Figure 1b). Considering the relative concentrations of these drugs, results show that K-877 activates the PPAR α transcription activity more effectively than the other agents. To determine the effects of K-877 on fibroblast growth factor 21 (*Fgf21*) expression, a typical target gene of PPAR α , *in vitro*, mouse AML12.2 hepatoma cells were incubated with the PPAR α agonists, Feno (50 μ mol/L) or K-877 (5 and 50 μ mol/L) for 48 h based on a previous report¹². Both doses of K-877 significantly increased *Fgf21* expression, but the increase in expression by Feno was slight (Figure 1c). Thus, K-877 can efficiently activate *Fgf21* expression.

K-877 decreased plasma lipid levels in WT mice

Based on a previous report⁷, 8-week-old male WT mice were fed a moderate-fat (MF) diet containing 0.2% (w/w) Feno or 0.001% (w/w) K-877 for 6 days. Although the dose of K-877 was 200-fold lower than that of Feno, compared with no treatment, K-877 and Feno significantly reduced plasma TG levels,




Figure 2 | K-877 reduces plasma lipid levels and increases the expression of hepatic fatty acid oxidation genes in wild type, but not in *Ppara*^{-/-} mice. Eight-week old male wild-type (WT) and *Ppara*^{-/-} mice were administrated with fenofibrate (Feno; 0.2%) or K-877 (0.001%) for 6 days. (a) Plasma triglyceride, total cholesterol and non-esterified fatty acid (NEFA) levels, and (b) hepatic gene expression in WT and *Ppara*^{-/-} mice; n = 9–13 per group; *P < 0.05 and **P < 0.01. mRNA, messenger ribonucleic acid.

and tended to reduce TC and NEFA levels (Figure 2a), and the effects of both agonists were blunted in *Ppara*^{-/-} mice (Figure 2a). These data show that considering the concentrations of agonists, K-877 elicits greater PPAR α -mediated lipid-lowering effects than Feno. Accordingly, hepatic gene expression of *Ppara* and its target genes, such as those encoding cyclic adenosine monophosphate responsive element binding protein 3-like 3 (*Creb3l3*), *Fgf21*, acyl-CoA oxidase 1, palmitoyl (*Acox1*) and carnitine palmitoyltransferase 1a, liver (*Cpt1a*), were significantly increased by both PPAR α agonists (Figure 2b). These changes in gene expression were similar in the presence of K-877 and Feno despite dose differences, showing that K-877 has more powerful effects on PPAR α activation than Feno. In addition, the effects of both agonists were abolished in *Ppara*^{-/-} mice, confirming that these agonists target the PPAR α pathway.

K-877 suppresses MCD-induced liver injury in normal mice, but not in *Ppara*^{-/-} mice

To compare the effects of PPAR α agonists on the progression of NAFLD, WT and *Ppara*^{-/-} mice were fed an MCD diet containing 0.1% Feno or 0.00025% K-877 for 4 weeks, and their optimum doses were determined according to previously

reported methods^{7,12}. This diet has been used extensively to produce diet-induced animal models of NASH that show similar histology to that of human NASH¹. Histological analyses of hematoxylin–eosin-stained liver sections from WT mice showed that the MCD diet led to slight lipid accumulation in hepatocytes (Figure 3a). The addition of Feno and K-877 suppressed MCD-induced lipid accumulation (Figure 3a). Furthermore, sections from MCD-fed *Ppara*^{-/-} mice showed greater lipid accumulation and macrophage invasion than those from MCD-fed WT mice, but the addition of Feno and K-877 could not improve them (Figure 3a). Hepatic TG and TC contents were significantly increased in MCD diet-fed mice than in MF diet-fed mice (Figure 3b). The addition of K-877 and Feno into MCD diets tended to reduce liver TG and TC levels, and *Ppara*^{-/-} mice showed more severe liver lipid accumulation than WT mice (Figure 3b). However, PPAR α agonists did not improve these phenotypes significantly (Figure 3b). In further analyses, increased plasma alanine aminotransferase and aspartate aminotransferase levels were observed in MCD diet-fed WT mice, compared with those in MF diet-fed WT mice (Figure 3c). The administration of K-877 or Feno tended to decrease MCD diet-induced alanine aminotransferase and aspartate aminotransferase levels. However, both agonists failed




Figure 3 | K-877 suppresses methionine–choline-deficient (MCD) diet-induced non-alcoholic fatty liver disease in wild-type (WT), but not in *Ppara*^{-/-} mice. Eight-week-old male WT and *Ppara*^{-/-} mice were fed moderate-fat (MF) or MCD diets containing fenofibrate (Feno; 0.1%) or K-877 (0.00025%) for 4 weeks. Hematoxylin–eosin staining in the (a) liver, (b) hepatic lipid contents, and (c) plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were determined in WT and *Ppara*^{-/-} mice; $n = 5$ –10 per group, * $P < 0.05$ and ** $P < 0.01$. TC, total cholesterol; TG, triglyceride.

to suppress these increases in *Ppara*^{-/-} mice (Figure 3c). Taken together, these data suggest that K-877 and Feno ameliorate MCD diet-induced fatty liver progression.

K-877 activates PPAR α target gene expression and reduces *Xbp1s* expression in the liver of MCD-fed mice

Hepatic gene expression was determined in WT and *Ppara*^{-/-} mice after feeding on a MCD diet containing PPAR α agonists for 4 weeks. Consistent with the expression levels of *Ppara* and its target genes *Creb3l3* in normal mice, *Acox1* and *Cpt1a* were significantly increased to similar levels in the presence of PPAR α agonists (Figure 4). However, *Fgf21* expression was decreased in the presence of PPAR α agonists. Furthermore, no apparent differences in inflammatory and macrophage hepatic gene expression were observed between MCD diet-fed WT mouse groups. The administration of PPAR α agonists on *Ppara*^{-/-} mice showed

increased *Cd68* expression, supporting the increase of macrophages including Kupffer cells. However, the MCD diet induced endoplasmic reticulum (ER) stress markers, such as X-box binding protein 1s (*Xbp1s*) in WT mice. In addition, the effects of K-877 on *Xbp1s* expression were abolished in *Ppara*^{-/-} mice. In subsequent experiments, K-877 suppressed MCD diet-induced *Xbp1s* expression more efficiently than Feno, thereby ameliorating ER stress in MCD diet-fed WT mice. In contrast, neither PPAR α agonist suppressed ER stress-related gene expression in *Ppara*^{-/-} mice. These data show that K-877 increases PPAR α target genes that are related to FA oxidation and reduces *Xbp1s* expression, leading to decreased liver injury.

DISCUSSION

In the present study, we showed that K-877 specifically and efficiently activates PPAR α transactivation activity *in vitro* and




Figure 4 | Hepatic gene expression in wild-type (WT) and *Ppara*^{-/-} mice fed the methionine–choline-deficient (MCD) diet with K-877 or fenofibrate (Feno) for 4 weeks. Eight-week-old male WT and *Ppara*^{-/-} mice were fed moderate-fat (MF) or MCD diets containing Feno (0.1%) or K-877 (0.00025%) for 4 weeks. Hepatic gene expression profiles of WT and *Ppara*^{-/-} mice; *n* = 5–10 per group; **P* < 0.05 and ***P* < 0.01. mRNA, messenger ribonucleic acid.

in vivo. Furthermore, K-877 had greater lipid-lowering effects than the classical PPAR α agonists in mice, and significantly induced PPAR α target genes. These effects reduced MCD-induced liver injury by increasing PPAR α target gene expression and decreasing ER stress in the liver. Therefore, K-877 might be an effective drug for hyperlipidemia.

Fibrates are widely used to ameliorate the macro- and microvascular risks associated with metabolic syndrome. However, these agents are weak PPAR α agonists, and have limited efficacy due to dose-related adverse events. To address this problem, a new generation of PPAR α -specific agonists, known as SPPARM α s, has been developed to maximize receptor-mediated effects and diminish side effects. In luciferase analyses, we confirmed that K-877 activates PPAR α at 1,000-fold lower doses than Feno and Wy. K-877 increases *Fgf21* expression, one of the typical target genes for PPAR α in AML12.2 cells. FGF21 is known to ameliorate obesity, diabetes and hyperlipidemia by inducing lipid catabolism^{13,14}. The *in vivo* studies showed that

K-877 and Feno induced the PPAR α target genes, *Fgf21*, *Acox1* and *Cpt1a*, in the liver of MF-fed WT mice, suggesting that these compounds activate hepatic FA oxidation. These effects were similar in the presence of low doses of K-877, or high doses of Feno, suggesting superiority of K-877 as a clinical agent. As a result, the administration of K-877 and Feno in MF-fed WT mice reduced plasma lipids, including TG, TC and NEFA. Previous reports have shown that some PPAR α agonists prevent the progression of NAFLD^{15,16}. Accordingly, K-877 efficiently increased the PPAR α transcriptional activity and subsequently transactivated FA oxidation genes, including *Acox1* and *Cpt1a*, resulting in reduced hepatic lipid accumulation in MCD-fed mice. However, *Fgf21* expression was decreased in MCD-fed WT mice in the presence of PPAR α agonist compared with that in MCD-fed WT mice without agonists. *Fgf21* expression was induced in both WT and *Ppara*^{-/-} mice in response to MCD, suggesting that a PPAR α independent mechanism underlies MCD-induced *Fgf21* expression.

ER stress is associated with an accumulation of misfolded and unfolded proteins in the ER lumen. ER plays an essential role in controlling lipid metabolism. XBP1s induces the expression of multiple inflammatory cytokines¹⁷, suggesting important roles of ER stress in the pathology of NAFLD. K-877 reduced hepatic *Xbp1s* expression, indicating potential roles in the management of ER stress. Furthermore, reduced lipid accumulation in the presence of K-877 might lead to decreases in the ER stress-related gene expression. Finally, the effects of K-877 in *Ppara*^{-/-} mice were blunted, confirming that this agonist specifically targets PPAR α .

Selective activation of PPAR α by K-877 was associated with beneficial changes in liver disease markers, suggesting the potential of this novel agent in the treatment of NASH/NAFLD might relate to PPAR α pathway activation and reduced ER stress. However, the mechanisms of K-877-mediated PPAR α activation remain unknown, warranting further studies to characterize the specificity of K-877 for PPAR α activation, recruitment of cofactors, and downstream gene expression.

ACKNOWLEDGMENT

This work was supported by JSPS KAKENHI, grant number 16H03253. This manuscript was edited by Enago English language editors.

DISCLOSURE

The authors declare no conflict of interest.

REFERENCES

1. Ip E, Farrell GC, Robertson G, *et al.* Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. *Hepatology* 2003; 38: 123–132.
2. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. *Lancet* 2001; 357: 905–910.
3. Bloomfield Rubins H, Davenport J, Babikian V, *et al.* Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). *Circulation* 2001; 103: 2828–2833.
4. Rubins HB, Robins SJ, Collins D, *et al.* Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. *N Engl J Med* 1999; 341: 410–418.
5. Tanne D, Koren-Morag N, Graff E, *et al.* Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. *Circulation* 2001; 104: 2892–2897.
6. The Bezafibrate Infarction Prevention (BIP) Study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. *Circulation* 2000; 102: 21–27.
7. Raza-Iqbal S, Tanaka T, Anai M, *et al.* Transcriptome Analysis of K-877 (a Novel Selective PPARalpha Modulator (SPPARMalpha))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver. *J Atheroscler Thromb* 2015; 22: 754–772.
8. Fruchart JC. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists. *Cardiovasc Diabetol* 2013; 12: 82.
9. Yamamoto T, Shimano H, Nakagawa Y, *et al.* SREBP-1 interacts with hepatocyte nuclear factor-4 alpha and interferes with PGC-1 recruitment to suppress hepatic gluconeogenic genes. *J Biol Chem* 2004; 279: 12027–12035.
10. Nakagawa Y, Shimano H, Yoshikawa T, *et al.* TFE3 transcriptionally activates hepatic IRS-2, participates in insulin signaling and ameliorates diabetes. *Nat Med* 2006; 12: 107–113.
11. Fujimoto Y, Nakagawa Y, Satoh A, *et al.* TFE3 controls lipid metabolism in adipose tissue of male mice by suppressing lipolysis and thermogenesis. *Endocrinology* 2013; 154: 3577–3588.
12. Hennuyer N, Duplan I, Paquet C, *et al.* The novel selective PPARalpha modulator (SPPARMalpha) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. *Atherosclerosis* 2016; 249: 200–208.
13. Badman MK, Pissios P, Kennedy AR, *et al.* Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. *Cell Metab* 2007; 5: 426–437.
14. Inagaki T, Dutchak P, Zhao G, *et al.* Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. *Cell Metab* 2007; 5: 415–425.
15. Jha P, Claudel T, Baghdasaryan A, *et al.* Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia. *Hepatology* 2014; 59: 858–869.
16. Chanda D, Lee CH, Kim YH, *et al.* Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. *Hepatology* 2009; 50: 880–892.
17. Martinon F, Chen X, Lee AH, *et al.* TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. *Nat Immunol* 2010; 11: 411–418.